Global Epilepsy Market  Volume, Value, Market Share, and Competition Landscape 2020 - 2023

Global Epilepsy Market by Condition (Epilepsy Drug Resistant/Intractable Epilepsy, Others), by Diagnosis & Treatment (Diagnosis & Treatment), by End-use (Hospitals, Clinics, Ambulatory Surgical Centers, Diagnostic Centers, Others), and Region - Forecast till 2023
Market Overview
Epilepsy is a major neurological disorder in which the brain activity becomes abnormal causing periods of unusual behavior and sensations. The disorder is noticeable in young children and young adults.
The Global Epilepsy Market is projected to touch a valuation of USD 9,509.2 million by 2023, exhibiting a CAGR of 8.20% over the forecast period (2018-2023). High prevalence of epilepsy among the geriatric population and increase in cases of brain injuries caused by accidents are major factors driving market growth.
The Epilepsy Market report offers insights into the leading market players and presents an assessment of their current market position. Company information with regards to revenue, segmental share, geographical income, SWOT, growth strategies, new product launch, M&A activities, and the latest R&D initiatives is also available in the report
Major Key Players
To gain a substantially large competitive advantage, these players incorporate strategic initiatives such as mergers & acquisitions, collaboration, expansion, and product launch. Some of the Top Key Players are, LivaNova PLC (U.K.), GlaxoSmithKline PLC (U.K.), Eisai Co. Ltd. (Japan), Pfizer Inc. (U.S.), Medtronic PLC (Ireland), UCB SA (Belgium), NeuroPace Inc. (U.S.), GW Pharmaceuticals PLC (U.K.), Novartis AG (Switzerland), Johnson & Johnson Services Inc. (U.S.), and Abbott Laboratories (U.S.).
Market Segment Analysis
The global Epilepsy Market is segmented by condition, diagnosis & treatment, and end-user.
By condition, the ‘others’ segment accounted for 70.5% market share in 2017. It is touted to reach a worth close to USD 6,571.40 million by 2023. On the other hand, the drug resistant epilepsy segment is projected to reach a valuation of USD 2,937.80 million by the end of the forecast period. Emergence of rational polytherapy for treating the disorder with negligible side-effects is likely to accrue significant revenue for the Epilepsy Market.
By diagnosis & treatment, the treatment segment held 66.2% share of the Epilepsy Market in 2017. The segment can exhibit 7.91% CAGR during the forecast period due to availability of affordable drugs for treating partial epileptic seizures. In addition, approval of effective drugs by regulatory agencies can facilitate growth in the segment. It is expected to be worth USD 6,198.63 million by 2023. On the other hand, the diagnosis segment is predicted to enjoy 8.76% CAGR over the assessment period. Utilization of various imaging tests and blood tests for early discernment of the disorder is expected to drive the segment growth exponentially. For instance, CT scans are used for revealing abnormalities in the brain which can catch the probability of epilepsy at an early stage.
By end-user, hospitals were the largest segment of the market with a valuation of USD 1,739.22 million in 2017. It is projected to exhibit a stellar 8.29% CAGR over the forecast period. On the other hand, clinics can showcase higher CAGR of 8.93% during the assessment period owing to clinics being a preferred center for diagnosis and treatment. In addition, adoption of latest equipment by doctors to provide excellent patient care can spur the growth of the segment.
Key Study Highlights:
  • This report for Epilepsy Market Research Future comprises of extensive primary research along with the detailed analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain the deeper insight of the market and industry performance.
  • The report gives the clear picture of current market scenario which includes historical and projected market size in terms of value and volume, technological advancement, macro economical and governing factors in the market. The report also gives a broad study of the different market segments and regions.
Regional Analysis
Geographically, the global Epilepsy Market has been divided into the Americas, Europe, Asia-Pacific, and the Middle East and Africa.
Browse Full Report Page Enabled with complete Table of Content at https://www.marketresearchfuture.com/reports/epilepsy-market-7730
About Market Research Future: MRFR often plans & conducts meet with the industry experts and industrial visits for its research analyst members.
Contact:
+1 646 845 9312 | Email: sales@marketresearchfuture.com

Comments

Post a Comment

Popular posts from this blog

Silicon Carbide Wafer Market Growth Opportunity, Size, Status and Forecast To 2026

  IDA Provides Silicon Carbide Wafer Growth Analysis 2021 Report by Key Players, Types, Applications, Countries, and Forecast. The Final Research Insights will get the complete Pandemic Impact Analysis on Information Technology & Telecommunication Category Till 2026: This Silicon Carbide Wafer Market research report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key players and the market as a whole. The global Industry growth depends on several factors that are Rising inclusion of artificial intelligence, automation, internet of things and others are expected to make sure that the market gains good mileage. Involving demand estimation, new product development and entry strategies, marketing and distribution strategies in the high-risk arena of new developments by helping you identify unmet needs. The Silicon Carbide Wafer Market Major Eminent players making significant moves in the global market have earned their ...
Read more

Global eClinical Solutions Market Key Companies, Global Expansion Strategies and Application Scope Till 2023

The  Global eClinical Solutions Market  is estimated to be valued at  USD 9434.57 million by 2023  and is expected to register a  CAGR of 12.24%  during the forecast period . The clinical data management system (CDMS) dominated the  global eClinical solutions market , by type, and is projected to reach  USD 2579 million by 2023  owing to the benefits offered by the product such as centralized end-to-end management of clinical trial activities, real-time status tracking, elimination of reliance on manual processes, and maintenance of multiple databases, which improve the overall efficiency of clinical trials. However, the electronic clinical outcome assessment (eCOA) segment is projected to be the fastest-growing segment during the forecast period. Americas dominated the market, accounting for the largest share of the market in 2017, and the regional market is expected to register a  CAGR of 12.41%  during the review perio...
Read more

Big Data in Healthcare Market Rising Trends, New Designs, Manufacturer Details, Forecasts to 2027

Big Data in Healthcare Market Research Report, by Hardware (Routers, VPNs), by Software (EHR, Practice Management), by Analytical service type (Descriptive, Predictive, Prescriptive) by region (Europe, Americas, APAC & MEA) – Forecast to 2027 The “ Big Data in Healthcare Market  ” In-Depth competition analysis of the major companies in the report, sector of the report includes the market depictions, requirements, and product portrayals, manufacture, competence, contact figures, cost, and revenue. The Big Data in Healthcare Market Free Growth Sample will provide valuable insight with an emphasis on the global market including some of the  major players  such As,  Cerner Corporation, Dell, Mckesson, Philips, Xerox, Cognizant, GE Healthcare,  Optum, Siemens, and others.. For Market Big Data in Healthcare Market analysis, the report covers upstream raw materials, equipment, downstream client survey, Marketing channels, Market development trend and propos...
Read more